Abstract
Combination chemotherapy with procarbazine, CCNU and vincristine (PCV) may be effective in patients with recurrent glioma. Response monitoring is mandatory, but radiological response evaluation is often difficult. We evaluated Thallium-201 (201Tl) SPECT as a response parameter in ten patients treated with intensive PCV chemotherapy for recurrent glioma. 201Tl-SPECT studies showed early changes (decreasing volume and intensity) in nine patients and these changes were more pronounced than radiological findings. 201Tl-SPECT results after completion of chemotherapy seemed to correlate with clininal findings during follow up. We conclude that 201Tl-SPECT may contribute to the assessment of response in patients treated with PCV chemotherapy for recurrent glioma.
| Original language | English |
|---|---|
| Pages (from-to) | 251-255 |
| Number of pages | 5 |
| Journal | Journal of neuro-oncology |
| Volume | 40 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1998 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chemotherapy
- Recurrent glioma
- Response parameter
- Thallium-201 SPECT
Fingerprint
Dive into the research topics of 'Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver